Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for Danicopan (Voydeya), which is being reviewed as an add-on to ravulizumab (Ultomiris™) or eculizumab (Soliris™) for the treatment of the signs or symptoms of extravascular hemolysis (EVH) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).